High Affinity Nanobodies Specific for Voltage Gated Sodium Channels
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Genetic channelopathies caused by mutations in voltage-gated sodium channels; including hypokalemic periodic paralysis, myotonia, and Brugada syndrome
Modality
Monoclonal Antibody
Mechanism
Nav channel nanobody
Target
Nav (voltage-gated sodium channels)
rNPV Envelope
Low
-$24.9M
costs +25% · peak −25%
Base
-$19.8M
cumulative PoS 0.6%
High
-$14.6M
costs −25% · peak +25%
This is an illustrative antibody/channelopathy envelope only. The actual asset reads as nanobody reagents/enabling tools for NaV channels, with therapeutic use unproven; PoS is reduced for ion-channel antibody mechanism risk and lack of a defined disease/isoform lead.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.65
Modality fit · 30%
0.51
Whitespace · 30%
0.50
Composite 0.564 — composite-score rank #49 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#13) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
NaV1.4 / NaV1.5 high-affinity nanobodies
The direct asset family: high-affinity nanobodies specific for voltage-gated sodium channel isoforms, useful as reagents and possible modulators.
Criteria 1: exact target/modality reality; tool/enabling anchor.
SVmab / NaV1.7 voltage-sensor antibody
Adjacent proof that antibodies can engage a voltage-gated sodium-channel extracellular voltage-sensor domain and alter function in preclinical pain/itch models.
Criteria 1 and 4: same ion-channel antibody concept, different isoform and indication; preclinical only.
NaV1.7 small-molecule blocker clinical class
Clinical sodium-channel drug-development cautionary anchor. The class has strong human genetics but difficult translation, underscoring why nanobodies should not be assumed therapeutic.
Criteria 4: same target family and translational challenge; not a same-modality comparator.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $8.0M | 24 mo | 26.0% | [0] [1] |
| Phase I | $35.0M | 18 mo | 50.0% | [1] [2] |
| Phase II | $90.0M | 30 mo | 18.0% | [1] [2] [3] |
| Phase III | $190.0M | 42 mo | 34.0% | [2] [3] |
| NDA/BLA Review | $12.0M | 12 mo | 80.0% | [2] |
Multiplier handling: Eligible multipliers (genetic_channelopathy_context) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$75.0M peak · WACC 16.0%
Peak revenue. For nanobody reagents/enabling tools, full drug peak is inappropriate. The $75M illustrative figure reflects possible tool licensing or a future partnered therapeutic option if one isoform/disease is selected.
WACC. NaV channel drug translation is difficult and the asset is not yet a defined therapeutic program.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$19.8M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$85.4M
P25
-$20.1M
P50 (median)
-$7.6M
P75
-$4.9M
P95
-$2.7M
Prob ≥ 0
0.0%
Evidence register
4 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is high-affinity NaV nanobody platform/tool cmo_findings.asset_class_reality | High Affinity Nanobodies Specific for Voltage Gated Sodium Channels regulatory | 2024-01-01 | high |
Primary NaV nanobody research anchor comparators[0] | Development of high-affinity nanobodies specific for NaV1.4 and NaV1.5 voltage-gated sodium channel isoforms peer_review | 2022-03-18 | high |
Antibody access to NaV extracellular voltage sensor is possible preclinically comparators[1] | A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief peer_review | 2014-06-12 | high |
NaV1.7 clinical translation is difficult stage_profile.phase_2.pos | A Review of the Therapeutic Targeting of SCN9A and NaV1.7 for Pain Relief in Current Human Clinical Trials peer_review | 2023-05-05 | high |
Thesis
Why this asset earns its rank
This is best classified as a research-tool/enabling nanobody asset, not a therapeutic program. Voltage-gated sodium channels do have extracellular voltage-sensor domains that antibodies can engage in preclinical work, so the mechanism is not impossible, but the JHU file does not define a disease lead, isoform-specific pharmacology, route, dose, or clinical candidate. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial.
Comparator economics are cautionary and tool-centered. NaV1.4/NaV1.5 nanobodies support reagent value; SVmab shows antibody access to a NaV1.7 voltage sensor is biologically possible; and NaV1.7 small-molecule trials show how hard sodium-channel translation can be despite strong human genetics. The engine result is -$24.9M to -$14.6M, with a base rNPV of -$19.8M and cumulative PoS of 0.6%; that is an illustrative future-option envelope, not a current drug valuation.
Verdict: useful enabling biology with potential partner interest, but not fundable as a drug yet. It earns its rank through channelopathy relevance and mAb-bucket scoring, while a CMO would first demand isoform, disease, functional modulation, and safety selectivity.
Key risks
Asset-specific, not generic biotech risks
- Asset-class mismatch: the current asset is nanobody reagent/enabling technology, not a defined therapeutic.
- Mechanism risk: binding a NaV channel does not imply safe functional correction of excitability disorders.
- Isoform safety risk: NaV1.4 and NaV1.5 are skeletal muscle and cardiac channel isoforms, so off-target or over-inhibition could be dangerous.
- Clinical translation risk: sodium-channel drug programs have struggled despite strong genetics, so PoS must stay conservative.